close

Morepen Laboratories Ltd

Know More
NSEBSE

37.100.80 (2.20%)

12:00 AM,29th Sep 2023

37.150.82 (2.26%)

12:00 AM,29th Sep 2023

BSE : 500288

NSE : MOREPENLAB

Sector : Health care

ISIN Code : INE083A01026

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 29 2023 | 12:00 AM IST

Market Cap (₹ Cr)

1896

Turnover (₹ Cr)

1.02

Volume (Shares)

2748499

Face Value

2

52-WK High

48.45

52-WK High Date

26 Dec 2022

52-WK Low

23.60

52-WK Low Date

03 Oct 2022

All Time High

218.00

All Time High Date

30 Mar 2000

All Time Low

2.05

All Time Low Date

07 Aug 2013

Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine Montelukast Sodium Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories such as antibiotics gastrointestinal respiratory analgesic antiallergic and neuropsychiatry with brands such as Saltum Saltumax Cefpopen Cefpen-S Dom-DT Acifix Rabipen- DSR and Montelast. It has new products added to the therapeutic categories including Kilbac Ducal D Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992 the company set up the new facilities for bulk manufacture of Cephalexin 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993 the company started implementing its expansion plans for manufacture Cephalexin 7ADCA CIMC Chloride Research and Development Block and Formulation unit. The company introduced two latest molecules Ketrolac Tromethamine and Omeprazole. Also the company also launched Loratadine and Cisapride. During the year 1993-1994 the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine which is a potent analgesic. During the year 1994-1995 the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.During the year 1995-1996 the company successfully launched high value and high technology products namely Cisapride & Loratadine. Also the company launched herbal product namely Paclitaxel an anti cancer drug. During the year 1996-1997 the company commissioned its own formulation unit which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001 the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland a proven international leader in blood group serology diagnostic products. Also the company developed and launched wide range of contemporary lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.During the year 2001-2002 the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005 the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year the company started finalizing marketing partner for filing ANDA's for the molecule. During the year 2005-2006 the company made 52 DMF filing across ten European countries for six products. Also the company broadened its offering by introduced new product like Ducal Rythmix Montelast Alcoflam Levopen Moezole and Cefpen-S. During the year 2006-2007 the company improved its presence in the key market of South East Asia Africa & Australia. During the year the company acquired more than fifty new prospective customers in Korea Japan and Taiwan. During the year the company started of OTC formulation under the umberalla brand 'Dr. Morepen'. During the year 2007-2008 the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor USA (for immuunohematology system & consumables) Teco Medical Instruments Germany (for coagulation system & consumables) InTec INC. (for ELISA Kits) Access Bio USA (for Rapid Malaria Kits) helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.

Morepen Laboratories Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

1896

EPS - TTM (₹) [S]

1.08

P/E Ratio (X) [S]

2.43

Face Value (₹) 2
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [S]15.26
P/B Ratio (₹) [S]2.43
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal Nifty Microcap 250 Index Fund-Reg (G) 0.91 235297 0.28
Motilal Oswal Nifty Microcap 250 Index Fund-Dir (G) 0.91 235297 0.28
Motilal Oswal S&P BSE Healthcare ETF 0.01 2606 0.13

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

36.25

37.50

Week Low/High

35.90

38.00

Month Low/High

35.65

42.00

Year Low/High

23.60

48.00

All time Low/High

2.05

218.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week2.06%1.92%-0.27-0.18%
1 Month-5.79%-5.84%1.161.53%
3 Month20.77%20.85%2.993.51%
6 Month50.81%51.12%14.2615.85%
1 Year52.36%52.67%16.7016.77%
3 Year58.55%58.89%73.3574.99%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
27-03-2023KAMLESH PUROHITNSEBUY562157027.62
27-03-2023KAMLESH PUROHITNSESELL562157027.43
26-12-2022GRAVITON RESEARCH CAPITAL LLPNSESELL432040541.78
26-12-2022GRAVITON RESEARCH CAPITAL LLPNSEBUY432040541.68
23-12-2022QE SECURITIESNSESELL467684840.90
23-12-2022QE SECURITIESNSEBUY452462140.98
23-12-2022TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITEDNSEBUY283385640.90
23-12-2022TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITEDNSESELL308290140.93
22-12-2022QE SECURITIESNSEBUY303045636.51
22-12-2022QE SECURITIESNSESELL334973436.44

Load More

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter38.22
Financial Institutions Banks0.98
Foreign Institutional Investors1.00
Insurance Companies1.06
Mutual Funds Uti0.00
Other Institutional Investors0.30
Indian Public45.49
Others Non Institutional Investors12.95
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Chairman & Managing Director : Sushil Suri

Non-Exec. & Independent Dir. : Manoj Joshi

Non-Exec. & Independent Dir. : Bhupender Raj Wadhwa

Non-Exec. & Independent Dir. : Sukhcharan singh

Company Sec. & Compli. Officer : Vipul Kumar Srivatava

Whole-time Director : Sanjay Suri

Non-Exec. & Independent Dir. : Praveen Kumar Dutt

Non-Exec. & Independent Dir. : Savita

Registered Office: Morepen Village, Nalagarh Road Near Baddi,Solan,Himachal Pradesh-173205 Ph: 91-01795-276201-03

Email:investors@morepen.com

URL:http://www.morepen.com